Karyopharm Therapeutics

Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress | Globe Newswire | 5/5/2020

… Date of June 23, 2020 – – Initiated Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 – – Conference Call Scheduled for Today at 8:30 a.m. ET – NEWTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of …

Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program | Globe Newswire | 4/29/2020

Title: Molecular Predictors of Response to Selinexor in Recurrent Glioblastoma Presenter: Christopher J. Walker, Karyopharm Therapeutics Inc. Abstract : 2565 Session: Central Nervous System Tumors About XPOVIO® (selinexor) XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and …

Follow Karyopharm Therapeutics:    

What Makes Karyopharm Therapeutics (KPTI) a Strong Momentum Stock: Buy Now? - April 27, 2020 - Zacks.com | 4/27/2020

… focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores , helps address this issue for us. Below, we take a look at Karyopharm Therapeutics ( KPTI - Free Report ) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score …

Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19 | PR Newswire | 4/22/2020

Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19 English – First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections – Precision for Medicine Responsible for Clinical Trial Management in Europe News provided by Apr 22, 2020, 09:08 ET Share this article BUDAPEST, Hungary , April 22, 2020 /PRNewswire/ – Precision for Medicine, a pioneer in the design, development and …

Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4) | Globe Newswire | 4/22/2020

… with the company as a strategic advisor in early 2018 and has been leading MYCAPSSA launch preparations over the last eight months. Previously, Mr. Varadan served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics , Inc., an oncology-focused pharmaceutical company, until July 2019 where he built their commercial organization and led preparations for the successful launch of Xpovio for multiple myeloma. Earlier in his career, Mr. Varadan held …

Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 Nasdaq:KPTI | Globe Newswire | 4/20/2020

NEWTON, Mass., Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to enroll approximately 230 patients at clinical sites in the U.S., Europe, and Israel. Selinexor is an oral selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1 which …

Drug Studied at Karmanos Cancer Institute Enters Clinical Trials for Treatment of COVID-19 | PR Newswire | 4/17/2020

DETROIT , April 17, An oral therapy that has been studied in laboratory experiments and clinical trials at the Barbara Ann Karmanos Cancer Institute , in partnership with Karyopharm Therapeutics Inc., will soon enter clinical trials for the treatment of COVID-19 and related viruses. The oral drug, selinexor (marketed as XPOVIO ® ), is currently approved at higher doses by the Food and Drug Administration (FDA) as a treatment for cancer patients with …

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma | PR Newswire | 4/14/2020

… dinucleotide (NAD), an essential metabolic cofactor and second messenger. Inhibition of NAMPT can effectively inhibit the energy metabolism and growth of tumor cells. In May 2018 , Antengene entered into a broad strategic collaboration with Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) and obtained exclusive rights for development and commercialization of four clinical stage, novel, oral drug candidates, including KPT-9274 (ATG-019), in various Asian countries and regions. As an oral small …

Insider Selling: Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Sells $186,100.00 in Stock | Daily Political | 4/13/2020

… 1.35 billion, a price-to-earnings ratio of -6.36 and a beta of 1.69. The firm has a 50 day simple moving average of $19.26 and a 200 day simple moving average of $16.21. Karyopharm Therapeutics Inc has a fifty-two week low of $4.26 and a fifty-two week high of $29.61. Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, February 13th. The company reported …

Michael Kauffman Sells 10,000 Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) Stock | 4/13/2020

… the company, valued at $10,516,920.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Michael Kauffman also recently made the following trade(s): Get Karyopharm Therapeutics alerts: On Wednesday, February 19th, Michael Kauffman sold 8,817 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $16.48, for a total transaction of $145,304.16. NASDAQ:KPTI opened at …

RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI) | 4/13/2020

RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI) Austin Angelo - April 13, 2020, 7:06 AM EDT SHARE ON: RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics ( KPTI ) today and set a price target of $34.00 . The company’s shares closed last Thursday at $20.53. According to TipRanks.com , Abrahams is a 5-star analyst with an average return of 8.5% and a 51.3% success rate …

Gilead Sciences (GILD) Receives a Buy from RBC Capital | 4/13/2020

… TipRanks.com , Abrahams is a 5-star analyst with an average return of 8.5% and a 51.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics . The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $77.44 average price target, implying a 4.1% upside from current levels. In a report issued …

Karyopharm Therapeutics (NASDAQ:KPTI) Earns Buy Rating from Royal Bank of Canada - Dakota Financial News | 4/13/2020

… objective on the stock. Royal Bank of Canada’s price target suggests a potential upside of 65.61% from the stock’s current price. Several other research analysts have also weighed in on the company. BidaskClub lowered Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 target price (up from $22.00) on shares …

SVB Leerink Analysts Increase Earnings Estimates for Karyopharm Therapeutics Inc (NASDAQ:KPTI) | 4/12/2020

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Research analysts at SVB Leerink increased their Q1 2020 EPS estimates for Karyopharm Therapeutics in a report issued on Tuesday, April 7th. SVB Leerink analyst J. Chang now anticipates that the company will earn ($0.54) per share for the quarter, up from their prior estimate of ($0.56). SVB Leerink currently has a “In-Line” rating and a $30.00 target price on the stock. SVB Leerink …

Analyzing Karyopharm Therapeutics (NASDAQ:KPTI) & MediciNova (NASDAQ:MNOV) | 4/12/2020

71.41% Risk & Volatility MediciNova has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Summary MediciNova beats Karyopharm Therapeutics on 8 of the 12 factors compared between the two stocks. About MediciNova MediciNova, Inc., a biopharmaceutical company, focuses on …

Insider Selling: Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Sells 10,000 Shares of Stock | 4/11/2020

… of the company’s stock, valued at $10,516,920.42. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink . Michael Kauffman also recently made the following trade(s): Get Karyopharm Therapeutics alerts: On Wednesday, February 19th, Michael Kauffman sold 8,817 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $16.48, for a total value of $145,304.16. Shares of KPTI traded …

Wedbush Reiterates Hold Rating for Karyopharm Therapeutics (NASDAQ:KPTI) | 4/11/2020

Wedbush reissued their hold rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report released on Tuesday, TipRanks reports. Wedbush currently has a $25.00 price target on the stock. Several other research analysts also recently commented on KPTI. BidaskClub downgraded Karyopharm Therapeutics from a strong-buy rating to a buy rating in a report on Friday, February 14th. Bank of America raised Karyopharm Therapeutics from an underperform rating …

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Expected to Announce Earnings of -$0.70 Per Share - Ticker Report | 4/11/2020

Wall Street brokerages predict that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will announce ($0.70) current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Karyopharm Therapeutics ’ earnings. The highest EPS estimate is ($0.54) and the lowest is ($0.76). Karyopharm Therapeutics reported earnings of ($1.09) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 35.8%. The firm is expected …

$21.86 Million in Sales Expected for Karyopharm Therapeutics Inc (NASDAQ:KPTI) This Quarter | 4/10/2020

Brokerages expect that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will post $21.86 million in sales for the current quarter, according to Zacks . Five analysts have provided estimates for Karyopharm Therapeutics’ earnings, with the lowest sales estimate coming in at $18.60 million and the highest estimate coming in at $28.30 million. Karyopharm Therapeutics posted sales of $160,000.00 in the same quarter last year, which would indicate a positive year-over-year growth …

Karyopharm Therapeutics Inc (NASDAQ:KPTI) to Post Q1 2020 Earnings of ($0.54) Per Share, SVB Leerink Forecasts | 4/10/2020

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Research analysts at SVB Leerink lifted their Q1 2020 EPS estimates for shares of Karyopharm Therapeutics in a report released on Tuesday, April 7th. SVB Leerink analyst J. Chang now anticipates that the company will post earnings of ($0.54) per share for the quarter, up from their previous forecast of ($0.56). SVB Leerink currently has a “In-Line” rating and a $30.00 target price on …

Wedbush Reaffirms “Hold” Rating for Karyopharm Therapeutics (NASDAQ:KPTI) | 4/10/2020

Wedbush Reaffirms “Hold” Rating for Karyopharm Therapeutics (NASDAQ:KPTI) Posted by Jeshia Costen on Apr 10th, 2020 // Comments off Wedbush reissued their hold rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note published on Tuesday, TipRanks reports. Wedbush currently has a $25.00 target price on the stock. KPTI has been the subject of a number of other research reports. SVB Leerink lifted their price target on shares …

Karyopharm Therapeutics (NASDAQ:KPTI) Given Hold Rating at Wedbush | 4/10/2020

Karyopharm Therapeutics (NASDAQ:KPTI) Given Hold Rating at Wedbush Posted by Trina Covell on Apr 10th, 2020 Wedbush reissued their hold rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note issued to investors on Tuesday morning, TipRanks reports. Wedbush currently has a $25.00 target price on the stock. KPTI has been the subject of several other reports. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a …

Komodo Health Teams Up with Karyopharm Therapeutics to Accelerate New Global Clinical Trial to Treat Patients with COVID-19 | 4/9/2020

… with severe COVID-19 ● In hours, Komodo’s Healthcare Map TM provided snapshot of virology and infectious disease patterns to inform trial site identification SAN FRANCISCO–( BUSINESS WIRE )– Komodo Health today announced a collaboration with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to accelerate clinical trial recruitment and site identification in an effort to speed patient access to a potential new treatment for COVID-19. The trial will evaluate whether low doses of …

UBS Asset Management Americas Inc. Buys 11,044 Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) - Transcript Daily | 4/9/2020

UBS Asset Management Americas Inc. increased its stake in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 20.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 65,176 shares of the company’s stock 11,044 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Karyopharm Therapeutics were worth $1,249,000 at the end of the most recent reporting period. A number of other institutional investors also recently modified …

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Reaffirmed by Wedbush - Ticker Report | 4/9/2020

… price target points to a potential upside of 29.67% from the stock’s previous close. A number of other equities analysts also recently weighed in on the company. HC Wainwright upped their price target on Karyopharm Therapeutics from $40.00 to $43.00 and gave the stock a “buy” report on Monday, March 2nd. JPMorgan Chase & Co. boosted their price target on Karyopharm Therapeutics from $23.00 to $27.00 and gave the stock an …

COVID-19

Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress | 5/5/2020

COVID-19 – – Conference Call Scheduled for Today at 8:30 a.m. ET – NEWTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO ® (selinexor), and provided an overview of its key clinical development programs. “I am extremely proud …

Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19 | 4/22/2020

Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19 English – First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections – Precision for Medicine Responsible for Clinical Trial Management in Europe News provided by Apr 22, 2020, 09:08 ET Share this article BUDAPEST, Hungary , April 22, 2020 /PRNewswire/ – Precision for Medicine, a pioneer in the design, development and …

Food and Drug Administration

Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Globe Newswire | 12/23/2019

NEWTON, Mass., Dec. 23, Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL) after at least …

Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress | Globe Newswire | 11/4/2019

November 04, 2019 07:00 ET Source: Karyopharm Therapeutics Inc. − XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO ® U.S. Net Product Sales of $12.8 Million with Over 500 … of the quarter following its accelerated approval by the U.S. Food and Drug Administration (FDA) in July. Rapid insurance coverage for XPOVIO has been a key contributor to its early commercial success with XPOVIO already …

Biotech

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug | Benzinga | 11/26/2019

Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals … NASDAQ: HZNP ) Incyte Corporation (NASDAQ: INCY ) Kamada Ltd. (NASDAQ: KMDA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO ) (announced a deal to be bought by Novartis AG (NYSE …

The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon | 11/21/2019

Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced FDA approval … NASDAQ: HZNP ) Incyte Corporation (NASDAQ: INCY ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) OptiNose Inc (NASDAQ: OPTN ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) ResMed Inc …

CRISPR

Nov 14, 2019 - Longwood Capital Partners LLC Buys Milestone Pharmaceuticals Inc, BELLUS Health Inc, Reata Pharmaceuticals Inc, Sells Iovance Biotherapeutics Inc, Adverum Biotechnologies Inc, Biohaven Pharmaceutical Holding Co - GuruFocus.com | 11/14/2019

Portola Valley, CA, based Investment company Longwood Capital Partners LLC ( Current Portfolio ) buys Milestone Pharmaceuticals Inc, BELLUS Health Inc, Reata Pharmaceuticals Inc, Karyopharm Therapeutics Inc, CRISPR Therapeutics AG, sells Iovance Biotherapeutics Inc, Adverum Biotechnologies Inc, Biohaven Pharmaceutical Holding Co, Veracyte Inc, Athenex Inc during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Longwood Capital Partners LLC. As of 2019Q3, Longwood Capital Partners LLC …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

… Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ …

Clinical Data

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

… DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX … Inc (NASDAQ: ALPN )(presented at a rheumatology conference new pre-clinical data for ALPN-101 in inflammatory/autoimmune diseases) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Capricor Therapeutics Inc (NASDAQ: CAPR Cellectar …

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting | Globe Newswire | 11/6/2019

November 06, 2019 10:12 ET Source: Karyopharm Therapeutics Inc. – Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed … key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company’s first in class, oral SINE compound, including: updated data from the Pomalyst® (pomalidomide) and Kyprolis® (carfilzomib) arms of …

Helius Medical Technologies

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

… DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX … Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Genocea Biosciences Inc (NASDAQ: GNCA ) Helius Medical Technologies Inc (NASDAQ: HSDT )(reported its third-quarter results) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Kezar Life Sciences Inc (NASDAQ: KZR ) Miragen Therapeutics Inc …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings | Benzinga | 11/6/2019

… Laboratories, Inc. (NYSE: BIO ) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Fulgent Genetics Inc (NASDAQ: FLGT ) ( reported forecast-beating third-quarter results) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) NextCure Inc (NASDAQ: NXTC ) (made a huge move ahead of … 52-week lows Nov. 5.) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Kezar Life Sciences Inc (NASDAQ: KZR ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Myriad Genetics, Inc …

CAR-T

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting | Globe Newswire | 11/6/2019

November 06, 2019 10:12 ET Source: Karyopharm Therapeutics Inc. – Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed … Investigating Selinexor in Patients whose Myeloma has Progressed Following Experimental CAR-T Therapy – NEWTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), an oncology-focused pharmaceutical company, today announced that thirteen abstracts …

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting Nasdaq:KPTI | Globe Newswire | 11/6/2019

CAR-T Therapy – NEWTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), an oncology-focused pharmaceutical company, today announced that thirteen abstracts have been selected for presentation, including one oral presentation, at the upcoming American Society of Hematology (ASH) 2019 Annual Meeting taking place December 7-10, 2019 in Orlando. Four key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company’s …

Medicare

Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress | Globe Newswire | 11/4/2019

November 04, 2019 07:00 ET Source: Karyopharm Therapeutics Inc. − XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO ® U.S. Net Product Sales of $12.8 Million with Over 500 … with XPOVIO already being added to numerous national commercial and Medicare formularies and coverage policies. Based on prescription fulfillment data through the specialty pharmacy channel, Karyopharm estimates that approximately 60% of XPOVIO prescriptions have been …

Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress | Benzinga | 11/4/2019

… the Middle of 2021 – − Conference Call Scheduled for Today at 8:30 a.m. ET − NEWTON, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (NASDAQ: KPTI ), an oncology-focused pharmaceutical company, today reported financial results for … with XPOVIO already being added to numerous national commercial and Medicare formularies and coverage policies. Based on prescription fulfillment data through the specialty pharmacy channel, Karyopharm estimates that approximately 60% of XPOVIO prescriptions have been …

Medicaid

Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress | Globe Newswire | 11/4/2019

November 04, 2019 07:00 ET Source: Karyopharm Therapeutics Inc. − XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO ® U.S. Net Product Sales of $12.8 Million with Over 500 … commercial insurance, with the remaining 5% of patients having either Medicaid or another form of prescription coverage. XPOVIO Receives Accelerated Approval from the FDA. On July 3, 2019, the FDA approved XPOVIO for use in …

Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress | Benzinga | 11/4/2019

… the Middle of 2021 – − Conference Call Scheduled for Today at 8:30 a.m. ET − NEWTON, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (NASDAQ: KPTI ), an oncology-focused pharmaceutical company, today reported financial results for … commercial insurance, with the remaining 5% of patients having either Medicaid or another form of prescription coverage. XPOVIO Receives Accelerated Approval from the FDA. On July 3, 2019, the FDA approved XPOVIO for use in …

EMR

CORRECTING and REPLACING XPOVIO™ (selinexor) Available for Order at Biologics by McKesson | Business Wire | 7/13/2019

… by McKesson , an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO™ (selinexor). XPOVIO is … electronic prescribing systems, physicians may search for Biologics within their EMR system. About Biologics by McKesson Biologics by McKesson is an independent specialty pharmacy with over 25 years of experience connecting patients to life-changing …

CORRECTING and REPLACING XPOVIO™ (selinexor) Available for Order at Biologics by McKesson | Business & Finance | heraldchronicle.com | Business Wire | 7/12/2019

… by McKesson , an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO™ (selinexor). XPOVIO is … electronic prescribing systems, physicians may search for Biologics within their EMR system. About Biologics by McKesson Biologics by McKesson is an independent specialty pharmacy with over 25 years of experience connecting patients to life-changing …

Komodo Health

Komodo Health Teams Up with Karyopharm Therapeutics to Accelerate New Global Clinical Trial to Treat Patients with COVID-19 | Business Wire | 4/8/2020

SAN FRANCISCO- Komodo Health today announced a collaboration with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to accelerate clinical trial recruitment and site identification in an effort to speed patient access to a potential new treatment for COVID-19. The trial will evaluate whether low doses of Karyopharm’s cancer medicine, selinexor, can also be effective at treating patients with severe COVID-19 based on anti-viral and anti-inflammatory properties of this …

Excelera

Excelera Expands Solutions for Members, Manufacturers and Payers, Improving Complex Patient Care in 2019 | PR Newswire | 1/7/2020

Excelera Expands Solutions for Members, Manufacturers and Payers, Improving Complex Patient Care in 2019 New specialty pharmacy services and products, health system members and top executive hires highlight 2019 accomplishments MINNEAPOLIS Excelera ® , the company responsible … LDDs) available to members The Excelera Network was selected by Karyopharm Therapeutics, Inc. to be in the limited drug distribution network for XPOVIO™ (selinexor), which was approved as a treatment for patients with multiple myeloma …

WageWorks

IPOs this week : Dec 2 - 6, 19 | 12/2/2019

… DATE) JILL Jive Software (JIVE) JMIA Jones Energy (JONE) Jounce Therapeutics (JNCE) Jumei (JMEI) JUNO KALA KaloBios (KBIO) Kamada (KMDA) Karyopharm Therapeutics (KPTI) Kayak Software (KYAK) KemPharm (KMPH) Kinder Morgan (KMI) Kindred Biosciences (KIN) King … Solar (VSLR) VMW VNCE Voxeljet (VJET) VSTO VTUS VYGR WAFU WageWorks (WAGE) warnings Warren Buffett Wayfair (W) WB WCI Communities (WCIC) WE wearable tech IPOs WEI Weibo (WB) Wesco Aircraft Holdings (WAIR) Western Refining Logistics …

Biocept

IPOs this week : Dec 2 - 6, 19 | 12/2/2019

… BIDU big drops big one-day moves Biggest First-Day Drops Biggest First-Day Gains biggest IPOs BILI BioAmber (BIOA) Biocept (BIOC) biotech IPOs Biotie Therapies (BITI) BITA BIVI BJ Black Knight Financial Group (BKFS … Therapeutics (JNCE) Jumei (JMEI) JUNO KALA KaloBios (KBIO) Kamada (KMDA) Karyopharm Therapeutics (KPTI) Kayak Software (KYAK) KemPharm (KMPH) Kinder Morgan (KMI) Kindred Biosciences (KIN) King (KING) KiOR (KIOR) Kips Bay Medical (KIPS) Kite Pharma (KITE …

Adaptimmune

IPOs this week : Dec 2 - 6, 19 | 12/2/2019

… year performance 8-month performance 9-month performance ABBV Abengoa Yield (ABY) ABT AC-TBD Acceleron Pharma (XLRN) Achaogen (AKAO) Adaptimmune Therapeutics (ADAP) ADCT Adeptus Health (ADPT) ADIL Admeld ADNT ADPT ADS Tactical (ADSI) ADT … Therapeutics (JNCE) Jumei (JMEI) JUNO KALA KaloBios (KBIO) Kamada (KMDA) Karyopharm Therapeutics (KPTI) Kayak Software (KYAK) KemPharm (KMPH) Kinder Morgan (KMI) Kindred Biosciences (KIN) King (KING) KiOR (KIOR) Kips Bay Medical (KIPS) Kite Pharma (KITE …

Novartis

Global Neuroendocrine Tumor Drug Market Insights Report 2019-2025: : Eisai, Exelixis, Inc., Foresee Pharmaceuticals, LLC | 12/1/2019

… Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Midatech Pharma Plc ., Millennium Pharmaceuticals, Inc., MolMed S.p.A., Northwest Biotherapeutics, Inc., Novartis AG, OctreoPharm Sciences GmbH, OXiGENE, Inc. to compete among themselves by offering better products and acceptable services to the clients and expand significantly at the global level. The global Neuroendocrine Tumor Drug market report offers summarized detail about the major market holding key contenders alongside the recent developing industries in the market …

OrbiMed

Orbimed Advisors LLC Sells 2,082,575 Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) - TheOlympiaReport | 11/29/2019

Orbimed Advisors LLC lessened its holdings in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 66.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,065,900 shares of the company’s stock after selling 2,082,575 shares during the quarter. Orbimed Advisors LLC owned 1.70% of Karyopharm Therapeutics worth $10,254,000 as of its most recent SEC filing. A number of other institutional investors …

Incyte

Stocks That Hit 52-Week Highs On Friday | Benzinga | 11/29/2019

… NASDAQ: PLMR ) stock made a new 52-week high of $54.71 Friday. The stock was up 1.08% for the day. Incyte (NASDAQ: INCY ) shares achieved a new 52-week high on Friday morning, hitting $94.99 … 39.82 Friday. The stock was up 2.37% for the day. Karyopharm Therapeutics (NASDAQ: KPTI ) stock hit a yearly high price of $18.50. The stock was up 4.69% for the day. SomnoMed (OTC: SOMNF ) stock on …

Amgen

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug | Benzinga | 11/26/2019

… Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas … NASDAQ: HZNP ) Incyte Corporation (NASDAQ: INCY ) Kamada Ltd. (NASDAQ: KMDA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO ) (announced a deal to be bought by Novartis AG (NYSE …

Seattle Genetics

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug | Benzinga | 11/26/2019

Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO ) (announced a deal to be bought by Novartis AG (NYSE: NVS ) Molecular Templates Inc (NASDAQ: MTEM ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Nevro Corp (NYSE: NVRO ) Qiagen NV (NYSE: QGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) (announced Health Canada approval for its sNDA for Adcetris along with chemotherapy for previously untreated lymphoma …

Vertex Pharmaceuticals

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug | Benzinga | 11/26/2019

… NYSE: GMED ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Incyte Corporation (NASDAQ: INCY ) Kamada Ltd. (NASDAQ: KMDA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO … for previously untreated lymphoma patients) Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 25.) Aethlon Medical, Inc. (NASDAQ: AEMD ) BAUDAX BIO …

Neurocrine Biosciences

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug | Benzinga | 11/26/2019

Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO ) (announced a deal to be bought by Novartis AG (NYSE: NVS ) Molecular Templates Inc (NASDAQ: MTEM ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Nevro Corp (NYSE: NVRO ) Qiagen NV (NYSE: QGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) (announced Health Canada approval for its sNDA for Adcetris along with chemotherapy for previously untreated lymphoma …

Epizyme

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug | Benzinga | 11/26/2019

Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Incyte Corporation (NASDAQ: INCY ) Kamada Ltd. (NASDAQ: KMDA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO ) (announced a deal to be bought by Novartis AG (NYSE: NVS …

Pacira

Alnylam R&D Day 2019 | 11/19/2019

… as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Boards of Acorda Therapeutics and Karyopharm Therapeutics. Jeff Poulton – Chief Financial Officer Jeff joined Alnylam as CFO in August 2019 … serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, and investment funds managed by Capital Research. Dr. Greenstreet also serves on the Scientific Advisory Committee of the …

Array BioPharma

Nov 14, 2019 - venBio Select Advisor LLC Buys Karyopharm Therapeutics Inc, Pacira BioSciences Inc, Athenex Inc, Sells Array BioPharma Inc, The Medicines Co, ACADIA Pharmaceuticals Inc - GuruFocus.com | 11/14/2019

San Francisco, CA, based Investment company venBio Select Advisor LLC ( Current Portfolio ) buys Karyopharm Therapeutics Inc, Pacira BioSciences Inc, Athenex Inc, uniQure NV, Adverum Biotechnologies Inc, sells Array BioPharma Inc, The Medicines Co, ACADIA Pharmaceuticals Inc, Adaptive Biotechnologies Corp, Intec Pharma during venBio Select Advisor LLC. As of 2019Q3, venBio Select Advisor LLC owns 32 stocks with a total value of $2.4 billion. These are the details of the buys …

Amarin

Nov 14, 2019 - Longwood Capital Partners LLC Buys Milestone Pharmaceuticals Inc, BELLUS Health Inc, Reata Pharmaceuticals Inc, Sells Iovance Biotherapeutics Inc, Adverum Biotechnologies Inc, Biohaven Pharmaceutical Holding Co - GuruFocus.com | 11/14/2019

… CA, based Investment company Longwood Capital Partners LLC ( Current Portfolio ) buys Milestone Pharmaceuticals Inc, BELLUS Health Inc, Reata Pharmaceuticals Inc, Karyopharm Therapeutics Inc, CRISPR Therapeutics AG, sells Iovance Biotherapeutics Inc, Adverum Biotechnologies Inc, Biohaven Pharmaceutical … 1.66%. The holding were 237,500 shares as of . New Purchase: Amarin Corp PLC ( AMRN ) Longwood Capital Partners LLC initiated holding in Amarin Corp PLC. The purchase prices were between $13.89 and $23.16, with an estimated …

Merck

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

… DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX … NASDAQ: VSTM ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Merck Acquires Calporta For Up To $576M COI Pharma, established by Avalon Ventures, said Merck & Co., Inc. (NYSE: MRK ) had acquired Calporta Therapeutics for a …

Celgene

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T …

Bristol-Myers Squibb

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex …

Allergan

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher | Benzinga | 11/13/2019

… last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals … GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX …

AmerisourceBergen

AmerisourceBergen Selected by Karyopharm to Support XPOVIO™ | Business & Finance | heraldchronicle.com | Business Wire | 10/1/2019

VALLEY FORGE, Pa.–(BUSINESS WIRE)–Oct 1, 2019– AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Karyopharm Therapeutics Inc. (Karyopharm) to support XPOVIO™ (selinexor). AmerisourceBergen is providing a unified commercialization approach for XPOVIO™, which was approved by the U.S. Food and Drug Administration (FDA) on July 3, 2019. XPOVIO™ is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult …

AbbVie

Global PARP Inhibitor Market to Surpass US$ 8,818.4 Million by 2027 - Coherent Market Insights | PR Newswire | 9/26/2019

AbbVie Inc., Bristol - Myers Squibb , Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd. Report Segmentation: Global PARP inhibitor Market, By Drug Type: Niraparib (Zejula) Olaparib (Lynparza) Rucaparib (Rubraca) Talazoparib (Talzenna) Global PARP inhibitor Market, By Application: Ovarian Cancer Breast Cancer Global PARP inhibitor Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Global PARP …

GlaxoSmithKline

Global PARP Inhibitor Market to Surpass US$ 8,818.4 Million by 2027 - Coherent Market Insights | PR Newswire | 9/26/2019

… to facilitate research and development of new therapies for treatment of ovarian and breast cancer. For instance, in January 2019 , GlaxoSmithKline plc. acquired TESARO, Inc. The acquisition is expected to help GlaxoSmithKline expand its portfolio … Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd. Report Segmentation: Global PARP inhibitor Market, By Drug Type: Niraparib (Zejula) Olaparib …

Pfizer

Global PARP Inhibitor Market to Surpass US$ 8,818.4 Million by 2027 - Coherent Market Insights | PR Newswire | 9/26/2019

… Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb , Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd. Report Segmentation: Global PARP inhibitor Market, By Drug Type: Niraparib (Zejula) Olaparib (Lynparza) Rucaparib (Rubraca) Talazoparib (Talzenna) Global PARP inhibitor Market, By Application: Ovarian Cancer Breast Cancer Global PARP inhibitor Market, By Distribution Channel: Hospital Pharmacies Retail …

Curaleaf

Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. | 9/18/2019

Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. PR Newswire NEW YORK, Sept. 17, 2019 NEW YORK , Sept. 17, 2019 /PRNewswire/ – Curaleaf

Zacks Investment Research

Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by Zacks Investment Research to “Hold” - TheOlympiaReport | 1/18/2020

Zacks Investment Research cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a strong-buy rating to a hold rating in a report released on Thursday morning, Zacks.com reports. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is …

Karyopharm Therapeutics (NASDAQ:KPTI) Raised to “Strong-Buy” at Zacks Investment Research | Daily Political | 1/15/2020

Zacks Investment Research upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a strong-buy note issued to investors on Tuesday, Zacks.com reports. Zacks Investment Research currently has $21.00 target price on the stock. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare …

Merrill Lynch

BofAML likes Alnylam in premarket analyst action - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) | Seeking Alpha | 11/13/2019

Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $110 (21% upside) price target at BofA Merrill Lynch. Arena Pharmaceuticals (NASDAQ: ARNA ) initiated with Neutral rating and $51 (11% upside) price target at BofAML. National Vision Holdings (NASDAQ: EYE ) initiated with Overweight rating and $34 (26% upside) price target at Barclays. Karyopharm Therapeutics (NASDAQ: KPTI ) added as Fresh Pick at Baird. Cerus (NASDAQ: CERS ) upgraded to Buy with a $7 …

Karyopharm Therapeutics Inc. (KTPI) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/16/2019

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KTPI) Q1 2019 Earnings Call May 9, 2019, 8:30 a.m. morning. My name is Gigi and I will be your conference operator. At this time, I would … next question is from Ying Huang from Bank of America Merrill Lynch. Your line is now open. Alec – Bank of America Merrill Lynch – Analyst Hey, guys. This is Alec on for Ying. My first question …

Zacks Equity Research

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates | Zacks | 11/4/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Karyopharm Therapeutics ( KPTI - Free Report ) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non …

Karyopharm Signs $150M Royalty Agreement to Support Xpovio | Zacks | 9/17/2019

Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Karyopharm Therapeutics Inc. ( KPTI - Free Report ) announced that it has entered into a royalty agreement for up to $150 million with private investment firm, HealthCare Royalty Partners. The deal was signed to support …

SVB Leerink

Karyopharm Therapeutics Inc (NASDAQ:KPTI) to Post FY2019 Earnings of ($3.23) Per Share, Svb Leerink Forecasts | 10/3/2019

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Analysts at Svb Leerink lowered their FY2019 earnings estimates for shares of Karyopharm Therapeutics in a note issued to investors on Monday, September 16th, Zacks Investment Research reports. Svb Leerink analyst J. Chang now anticipates that the company will post earnings per share of ($3.23) for the year, down from their previous forecast of ($3.21). Svb Leerink also issued estimates for Karyopharm Therapeutics’ Q4 2019 …

Karyopharm Therapeutics Inc. (KPTI) CEO Dr. Michael Kauffman on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

Karyopharm Therapeutics Inc. (NASDAQ: KPTI ) Q1 2019 Results Conference Call May 9, 2019 8:30 AM ET Company Participants Ian Karp - VP, IR and Public Relations Dr. Michael Kauffman - CEO Mike Mason - CFO Anand Varadan - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets David Ruch - SVB Leerink Operator Good morning. My name is Gigi and I will be your conference operator today. At this time, I would like …

HealthCare Royalty Partners

Karyopharm Signs $150M Royalty Agreement to Support Xpovio | Zacks | 9/17/2019

Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Karyopharm Therapeutics Inc. ( KPTI - Free Report ) announced that it has entered into a royalty agreement for up to $150 million with private investment firm, HealthCare Royalty Partners. The deal was signed to support …

Karyopharm inks royalty agreement with HCR; shares up 3% premarket - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) | Seeking Alpha | 9/16/2019

Karyopharm Therapeutics (NASDAQ: KPTI ) has entered into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150M to support the development and commercialization of XPOVIO (selinexor), an oral selective inhibitor of nuclear export compound, for the treatment of patients with heavily pretreated multiple myeloma. Under the terms of the agreement, Karyopharm will receive $75M at closing this month and is eligible to receive an additional $75M upon the …

Ridgeback Capital

Karyopharm Therapeutics Inc (KPTI) Holdings Boosted by Spark Investment Management LLC - American Banking News | 5/21/2019

Spark Investment Management LLC raised its position in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 54.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned … investors have also recently bought and sold shares of KPTI. Ridgeback Capital Investments L.P. acquired a new position in Karyopharm Therapeutics in the 4th quarter valued at about $36,967,000. Emerald Advisers LLC boosted its holdings …

Karyopharm Therapeutics Inc (KPTI) Holdings Lifted by Candriam Luxembourg S.C.A. | 5/8/2019

Posted by ABMN Staff on May 8th, 2019 // No Comments Candriam Luxembourg S.C.A. grew its holdings in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 4.1% during the first quarter, according to the company in … 72,556,000 after buying an additional 204,897 shares during the period. Ridgeback Capital Investments L.P. purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth $36,967,000. FMR LLC raised its position in …

RBC Capital Markets

Karyopharm Therapeutics Inc. (KTPI) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/16/2019

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KTPI) Q1 2019 Earnings Call May 9, 2019, 8:30 a.m. morning. My name is Gigi and I will be your conference operator. At this time, I would … been stated. Our first question is from Brian Abrahams from RBC Capital Markets. Your line is now open. Brian Abrahams – RBC Capital Markets – Analyst My first question – what efficacy data would you be able to …

Karyopharm Therapeutics Inc. (KPTI) CEO Dr. Michael Kauffman on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

Karyopharm Therapeutics Inc. (NASDAQ: KPTI ) Q1 2019 Results Conference Call May 9, 2019 8:30 AM ET Company Participants Ian Karp - VP, IR and Public Relations Dr. Michael Kauffman - CEO Mike Mason - CFO Anand Varadan - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets David Ruch - SVB Leerink Operator Good morning. My name is Gigi and I will be your conference operator today. At this time, I would like …

UPMC

CVS Health, Pfizer, UPMC Health Plan, Karyopharm Therapeutics, Trestle Compliance, Asembia, and More to Speak at World Congress’ Integrate19 Congress in Philadelphia - news - Cincinnati Bell | 7/8/2019

UPMC Health Plan - Chris Primiano, Executive Vice President, Chief Business Officer, General Counsel for Karyopharm Therapeutics - L. Stephan Vincze, JD, LLM, MBA, President and Chief Executive Officer, Trestle Compliance - Jennifer McGee, Vice President and Chief Compliance Officer of Otsuka Just added: - Lisa Rachlin, Associate Director, and Corporate Counsel at Vertex Pharma - Snehal Patel, PharmD, Vice President, Pharmacy & Access Solutions at Asembia - Andy Bramlett, Senior Director, Specialty Channel Strategy at Takeda …

CVS Health, Pfizer, UPMC Health Plan, Karyopharm Therapeutics, Trestle Compliance, Asembia, and More to Speak at World Congress’ Integrate19 Congress in Philadelphia - news - GVTC | 7/8/2019

UPMC Health Plan - Chris Primiano, Executive Vice President, Chief Business Officer, General Counsel for Karyopharm Therapeutics - L. Stephan Vincze, JD, LLM, MBA, President and Chief Executive Officer, Trestle Compliance - Jennifer McGee, Vice President and Chief Compliance Officer of Otsuka Just added: - Lisa Rachlin, Associate Director, and Corporate Counsel at Vertex Pharma - Snehal Patel, PharmD, Vice President, Pharmacy & Access Solutions at Asembia - Andy Bramlett, Senior Director, Specialty Channel Strategy at Takeda …

Michael Kauffman

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 6.2% on Insider Selling - Ticker Report | 1/15/2020

Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s share price dropped 6.2% during trading on Monday after an insider sold shares in the company. The stock traded as low as $17.10 and last traded at $17.24, approximately 1,783,471 shares changed hands during mid-day trading. An increase of 55% from the average daily volume of 1,150,000 shares. The stock had previously closed at $18.38. Specifically, CEO Michael Kauffman sold 20,000 shares of …

Michael G. Kauffman

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update | Globe Newswire | 1/13/2020

… 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 – NEWTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) – Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), an oncology-focused pharmaceutical company, today announced preliminary unaudited fourth … U.S., indicated for patients with heavily pretreated multiple myeloma,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “We are extremely pleased with the commercial launch of XPOVIO thus far, including the breadth …

Kahn Swick

KARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI | Globe Newswire | 9/23/2019

September 22, 2019 22:50 ET Source: Kahn Swick & Foti, LLC NEW ORLEANS, La., Sept. 22, Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). Investor losses must relate …

Lewis Kahn

KARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI | Globe Newswire | 9/23/2019

… that they have only until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). Investor losses must relate to purchases of the Company’s shares … without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-kpti/ to learn more. If you wish to …

Brian Schall

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Globe Newswire | 9/23/2019

… ANGELES, The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI ) for violations of §§10(b) and … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

Bragar Eagel

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm | Malvern Daily Record | 9/21/2019

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. ( NASDAQ: KPTI ) securities between March 2, 2017 to February 22, 2019 (the “Class Period”). Investors have until September 23, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here …

Peretz Bronstein

INVESTOR ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 | Globe Newswire | 9/20/2019

… 2019 (GLOBE NEWSWIRE) – Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) and certain of its officers, on … visit the firm’s site: www.bgandg.com/kpti or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Karyopharm you …

Yael Hurwitz

INVESTOR ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 | Globe Newswire | 9/20/2019

… 2019 (GLOBE NEWSWIRE) – Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) and certain of its officers, on … may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Karyopharm you have until September 23, 2019 to request that …

Richard Gonnello

KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm | 9/20/2019

KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm New York, NY - ( NewMediaWire ) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities … obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected] CONTACT: 685 Third Avenue, 26th FloorNew York …

Joshua Lifshitz

Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. | 9/18/2019

Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. Lifshitz & Miller LLP Announces Investigation of Curaleaf … our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected] . Granite Construction, Inc. (GVA) Lifshitz & Miller announces investigation into possible securities …

Robert S. Willoughby

Pomerantz Law Firm Announces the Filing of a Class Action against Karyopharm Therapeutics Inc. and Certain Officers – KPTI | Globe Newswire | 9/17/2019

… 2019 19:44 ET Source: Pomerantz LLP NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) and certain of its officers. The … can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include …

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. | Globe Newswire | 9/16/2019

September 16, 2019 10:30 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI ) investors that: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019 , inclusive …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. | Globe Newswire | 9/16/2019

… the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI ) investors that: (1) purchased shares of … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019 …

Phillip Kim

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action – KPTI | Globe Newswire | 9/13/2019

… Law Firm PA NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) – Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through … go to http://www.rosenlegal.com/cases-register-1633.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN …

Abraham L. Pomerantz

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI | Globe Newswire | 9/5/2019

… September 05, 2019 15:44 ET Source: Pomerantz LLP NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact … corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than …

Laurence Rosen

ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – KPTI | Business Wire | 8/9/2019

NEW YORK- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”) of … Attorney advertising. Prior results do not guarantee future outcomes. Contacts Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll …

Mike Mason

Karyopharm Therapeutics Inc. (KTPI) Q1 2019 Earnings Call Transcript | Yahoo News | 5/17/2019

Logo of jester cap with thought bubble with words ‘Fool Transcripts’ below it More Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KTPI) Q1 2019 Earnings Call May 9, 2019, 8:30 a.m. ET Contents: Prepared … today by Dr. Michael Kauffman, our Chief Executive Officer, Mr. Mike Mason, Chief Financial Officer, Mr. Christopher Primiano, Chief Business Officer and General Counsel, and Mr. Anand Varadan, our Chief Commercial Officer. On the call …